OpGen, Inc. (OPGN)

Market Cap	4.54M
Revenue (ttm)	3.31M
Net Income (ttm)	-40.73M
Shares Out	3.22M
EPS (ttm)	-18.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	795,866
Open	1.50
Previous Close	1.55
Day's Range	1.31 - 1.54
52-Week Range	0.93 - 17.56
Beta	-0.22
Analysts	Sell
Price Target	32.23 (+2,185.82%)
Earnings Date	Apr 4, 2023

About OPGN

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also com...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: May 5, 2015
• Employees: 91
• Stock Exchange: NASDAQ
• Ticker Symbol: OPGN

Financial Performance

In 2021, OpGen's revenue was $4.31 million, an increase of 2.17% compared to the previous year's $4.21 million. Losses were -$41.97 million, 60.1% more than in 2020.

Analyst Forecast

According to 6 analysts, the average rating for OPGN stock is "Sell." The 12-month stock price forecast is $32.23, which is an increase of 2,185.82% from the latest price.

Price Target

$32.23

(2,185.82% upside)

Analyst Consensus: Sell